Table 1 Summary of participant demographic and clinical characteristics (n = 661)^a

N

661

458

176

Age (years)

67.6 (8.1) [55, 89]

68.8 (8.4) [55, 89]

64.7 (6.5) [55, 85]

<.001

Sex

.158

 Male

217 (32.8)

157 (34.3)

50 (28.4)

 Female

444 (67.2)

301 (65.7)

126 (71.6)

Educational attainment

<.001

  ≤ 12 years

386 (58.4)

306 (66.8)

80 (46.2)

  > 12 years

245 (37.1)

152 (33.2)

93 (53.8)

 Missing

30 (4.5)

–

–

ESR (mm/hr) (n = 532)

22.6 (21.1) [1, 137]

23.7 (21.4) [1, 137]

17.1 (16.9) [1, 105]

.002

DAS28-ESRscore (n = 337)

3.5 (1.5) [0.63, 7.85]

3.6 (1.5) [0.63, 7.85]

3.1 (1.3) [1.21, 6.74]

.007

Disease duration (years) (n = 556)

12.6 (12.9) [0, 73]

12.8 (13.2) [0, 73]

12.2 (12.0) [0, 60]

.618

Disease activity

.079

 Remission (DAS28 ≤ 2.6)

92 (13.9)

61 (13.3)

31 (17.6)

 Low (2.6 < DAS ≤ 3.2)

60 (9.1)

38 (8.3)

21 (11.9)

 Moderate (3.2 < DAS ≤ 5.1)

135 (20.4)

101 (21.1)

31 (17.6)

 High (DAS > 5.1)

50 (7.6)

40 (8.7)

9 (5.1)

 Missing

324 (49.0)

218 (47.6)

84 (47.7)

Anti-CCP

.505

 Positive

267 (40.4)

201 (43.9)

56 (31.8)

 Negative

156 (23.6)

113 (24.7)

37 (21.0)

 Missing

238 (36.0)

144 (31.4)

83 (47.2)

RF

.141

 Positive

300 (45.4)

223 (48.7)

68 (38.6)

 Negative

137 (20.7)

93 (20.3)

40 (22.7)

 Missing

224 (33.9)

142 (31.0)

68 (38.6)

RA Medication

.731

 csDMARD + TNFi

125 (18.9)

97 (21.2)

26 (14.8)

 csDMARD only

393 (59.5)

293 (64.0)

86 (48.9)

 TNFi only

74 (11.2)

54 (11.8)

19 (10.8)

 Missing

69 (10.4)

14 (3.1)

45 (25.6)

Taking prednisolone

.743

 Yes

37 (5.6)

27 (5.9)

9 (5.1)

 No

555 (84.0)

417 (91.0)

122 (69.3)

 Missing

69 (10.4)

14 (3.1)

45 (25.6)

Taking NSAID

.149

 Yes

80 (12.1)

56 (12.2)

23 (13.1)

 No

512 (77.5)

388 (84.7)

108 (61.4)

 Missing

69 (10.4)

14 (3.1)

45 (25.6)